BRIEF published on 09/19/2025 at 18:05, 10 months 17 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 1 year ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
BRIEF published on 07/25/2025 at 07:35, 1 year ago Advicenne Announces 9% Revenue Growth for H1 2025 Growth Turnover Advicenna Sibnayal® Pharmaceutical Markets
PRESS RELEASE published on 07/25/2025 at 07:30, 1 year ago Inside Information / Other news releases Advicenne reports H1 2025 sales of €2.6 million, with direct sales rising 17% and Sibnayal® sales in Europe up 90% compared to H1 2024. Company's cash flow horizon extends to Q3 2026 Cash Flow Pharmaceutical Advicenne Sibnayal H1 2025 Sales
BRIEF published on 07/21/2025 at 20:57, 1 year ago Advicenne raises 2.6 million euros to strengthen its financial capacity Capital Increase Financial Market Bpifrance Kidney Diseases Advicenna
BRIEF published on 03/27/2025 at 19:17, 1 year 4 months ago Advicenne Reports Solid Growth and Future Plans for 2025 Cash Flow Improvement 2025 Outlook Advicenne Financial Results Sibnayal Sales Growth ADV7103 Regulatory Progress
PRESS RELEASE published on 03/27/2025 at 19:12, 1 year 4 months ago Inside Information / News release on accounts, results Advicenne reports successful commercial performance of Sibnayal® in Europe, with total product sales up 9.4% to €4.9m. Major strides in US development with NDA filing expected in Q3 2025 Financial Results Advicenne Commercial Performance Sibnayal US Development
BRIEF published on 10/01/2024 at 07:05, 1 year 10 months ago Advicenne Advances in US with Positive FDA Reviews for ADV7103 FDA ADV7103 ATRd Advicenna Cystinuria
PRESS RELEASE published on 10/01/2024 at 07:00, 1 year 10 months ago Inside Information / Other news releases Advicenne achieves major milestones in the US with positive FDA opinions on ADV7103, accelerating partnership outlook for commercialization, preparing for clinical development in cystinuria, and seeking commercial partners Commercialization Advicenne ADV7103 Cystinuria FDA Opinions
Published on 08/06/2026 at 22:00, 9 minutes ago Gold Terra Announces Closing of Second Tranche of the C$10.8M LIFE
Published on 08/06/2026 at 15:00, 7 hours 9 minutes ago Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 7 hours 39 minutes ago Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 7 hours 39 minutes ago NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 7 hours 39 minutes ago AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 21:45, 24 minutes ago FP Markets Analysis: Japanese Yen at a Crossroads as Markets Weigh Next Move
Published on 08/06/2026 at 19:05, 3 hours 4 minutes ago Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEO
Published on 08/06/2026 at 18:24, 3 hours 44 minutes ago EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026
Published on 08/06/2026 at 17:20, 4 hours 49 minutes ago Strutt Enters Europe: Expands Product Lineup with New ev¹e Variant and Showcases Evolving Smart Ecosystem at IFA 2026
Published on 08/06/2026 at 18:26, 3 hours 43 minutes ago Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 4 hours 24 minutes ago Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:35, 4 hours 34 minutes ago Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 4 hours 34 minutes ago Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026
